Juan Carlos Pinto  Cardenas

Ms. Juan Carlos Pinto Cardenas

Diagnostico de Salud Animal SA de CV, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CPChristopher J Pinard
Christopher J Pinard
WTWilliam Tran
William Tran
FLFang-I Lu
Fang-I Lu
JKJonathan Klein
Jonathan Klein
MOMichelle Oblak
Michelle Oblak
WTWilliam Tyler Tran
William Tyler Tran
Despite the important role of preclinical experiments to characterize tumor biology and molecular pathways, there are ongoing challenges to model the tumor microenvironment, specifically the dynamic interactions between tumor cells and immune infiltrates. Comprehensive models of host-tumor immune interactions will enhance the development of emerging treatment strategies, such as immunotherapies. Although in vitro and murine models are important for the early modelling of cancer and treatment-response mechanisms, comparative research studies involving veterinary oncology may bridge the translational pathway to human studies. The natural progression of several malignancies in animals exhibits similar pathogenesis to human cancers, and previous studies have shown a relevant and evaluable immune system. Veterinary oncologists working alongside oncologists and cancer researchers have the potential to advance discovery. Understanding the host-tumor-immune interactions can accelerate drug and biomarker discovery in a clinically relevant setting. This review presents discoveries in comparative immuno-oncology and implications to cancer therapy.

3 September 2024 in Cells
Verified
Journal Article
Open access
PDF file
PSPetra Sergent
Petra Sergent
JCJuan Carlos Pinto Cardenas
Juan Carlos Pinto Cardenas
ACAdhara Jaciel Arreguin Carrillo
Adhara Jaciel Arreguin Carrillo
DDDaniel Luna Dávalos
Daniel Luna Dávalos
MGMarisa Daniela González
Marisa Daniela González
Hugo Arias-PulidoHugo Arias-Pulido
Hugo Arias-Pulido
Neoadjuvant intratumoral (IT) therapy could amplify the weak responses to checkpoint blockade therapy observed in breast cancer (BC). In this study, we administered neoadjuvant IT anti-canine PD-1 therapy (IT acPD-1) alone or combined with IT cowpea mosaic virus therapy (IT CPMV/acPD-1) to companion dogs diagnosed with canine mammary cancer (CMC), a spontaneous tumor resembling human BC. CMC patients treated weekly with acPD-1 (n = 3) or CPMV/acPD-1 (n = 3) for four weeks or with CPMV/acPD-1 (n = 3 patients not candidates for surgery) for up to 11 weeks did not experience immune-related adverse events. We found that acPD-1 and CPMV/acPD-1 injections resulted in tumor control and a reduction in injected tumors in all patients and in noninjected tumors located in the ipsilateral and contralateral mammary chains of treated dogs. In two metastatic CMC patients, CPMV/acPD-1 treatments resulted in the control and reduction of established lung metastases. CPMV/acPD-1 treatments were associated with altered gene expression related to TLR1–4 signaling and complement pathways. These novel therapies could be effective for CMC patients. Owing to the extensive similarities between CMC and human BC, IT CPMV combined with approved anti-PD-1 therapies could be a novel and effective immunotherapy to treat local BC and suppress metastatic BC.

23 May 2026 in Cells
Verified
Journal Article
Open access
PDF file
CHColin J. Hartman
Colin J. Hartman
PSPetra Sergent
Petra Sergent
AZAnna Barbara Emilia Zimmermann
Anna Barbara Emilia Zimmermann
OCOlga Regina Chávez
Olga Regina Chávez
LPLuis Alberto Pérez
Luis Alberto Pérez
Hugo Arias-PulidoHugo Arias-Pulido
Hugo Arias-Pulido
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.